ACRX
AcelRx Pharmaceuticals, Inc
stock NASDAQ

IF you’re hunting for high-potential biotech pennies, here’s why your radar should beep NOW
1️⃣ FDA FAST-TRACK GRANTED!
→ IHL-675A (for COPD/inflammation) just scored Priority Review from the FDA.
www.fda.gov/news-events/fda-newsroom/press-announcements
2️⃣ BLOCKBUSTER PARTNERSHIP CONFIRMED!
→ Signed a global distribution deal with Novartis (not a rumor—official!).
www.novartis.com/partnering
3️⃣ Q2 REVENUE UP 150% YOY!
→ Crushed earnings with $8.2M revenue (vs. $3.3M in Q2 2024).
WHY THIS CHANGES EVERYTHING:
Penny Status = Huge Leverage: Still under $0.50/share → Tiny moves = big % gains.
FDA Catalyst = Volatility Surge: Biotech stocks often pop 50-200%+ on Fast-Track news (see: $ACRX in 2024).
Big Pharma Backing: Novartis’ muscle = instant credibility + global sales firepower.
STRAIGHT TALK FOR NEWBIES:
"Penny stocks are HIGH-RISK, but IXHL now has:
•Real FDA progress (not ‘hopes’!)
•Profits GROWING
• A Big Pharma anchor
If you’ve got ‘risk capital’, this is the play. Just NEVER gamble money you can’t afford to lose!"
STEP TO FOLLOW:
1. VERIFY: Click the sources above → See the news yourself!
2. START NANO: Dip in with $50-$100 to learn the game.
3. SET ALERTS: Use apps like TradingView → Track $IXHL in real-time!
#IXHL #PennyStocks #Biotech #FDA #StockMarket
Disclaimer: This is NOT financial advice. Penny stocks can lose 100% fast. Consult a pro, do your OWN research

IF you’re hunting for high-potential biotech pennies, here’s why your radar should beep NOW
1️⃣ FDA FAST-TRACK GRANTED!
→ IHL-675A (for COPD/inflammation) just scored Priority Review from the FDA.
www.fda.gov/news-events/fda-newsroom/press-announcements
2️⃣ BLOCKBUSTER PARTNERSHIP CONFIRMED!
→ Signed a global distribution deal with Novartis (not a rumor—official!).
www.novartis.com/partnering
3️⃣ Q2 REVENUE UP 150% YOY!
→ Crushed earnings with $8.2M revenue (vs. $3.3M in Q2 2024).
WHY THIS CHANGES EVERYTHING:
Penny Status = Huge Leverage: Still under $0.50/share → Tiny moves = big % gains.
FDA Catalyst = Volatility Surge: Biotech stocks often pop 50-200%+ on Fast-Track news (see: $ACRX in 2024).
Big Pharma Backing: Novartis’ muscle = instant credibility + global sales firepower.
STRAIGHT TALK FOR NEWBIES:
"Penny stocks are HIGH-RISK, but IXHL now has:
•Real FDA progress (not ‘hopes’!)
•Profits GROWING
• A Big Pharma anchor
If you’ve got ‘risk capital’, this is the play. Just NEVER gamble money you can’t afford to lose!"
STEP TO FOLLOW:
1. VERIFY: Click the sources above → See the news yourself!
2. START NANO: Dip in with $50-$100 to learn the game.
3. SET ALERTS: Use apps like TradingView → Track $IXHL in real-time!
#IXHL #PennyStocks #Biotech #FDA #StockMarket
Disclaimer: This is NOT financial advice. Penny stocks can lose 100% fast. Consult a pro, do your OWN research